Hereditärt angioödem - svår sjukdom med nya terapialternativ

Lakartidningen

Volumn 109, Issue 3, 2012, Pages 99-103

  Björkander, Janne ^a,b   Bygum, Anette ^c   Nielsen, Erik Waage ^d  

^a Lung Allergimottagningen   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Odense Universitetssjukhus ^*  (Denmark)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN; ANTIFIBRINOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COMPLEMENT INHIBITOR;

ADOLESCENT; ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; ERYTHEMA; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANABOLIC AGENTS; ANDROGENS; ANGIOEDEMAS, HEREDITARY; ANTIFIBRINOLYTIC AGENTS; CHILD; COMPLEMENT INACTIVATING AGENTS; ERYTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84856183558     PISSN: 00237205     EISSN: 16527518     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin- receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363:532-41.
2. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol. 2009;161:1153-8.
3. Roche O, Blanch A, Duponchel C, Fontan G, Tosi M, Lopez-Trascasa M. Hereditary angioedema: the mutation spectrum of SERPING1/ C1NH in a large Spanish cohort. Hum Mutat. 2005;26:135-44.
4. Nielsen EW, Johansen HT, Holt J, Mollnes TE. C1 inhibitor and diagnosis of hereditary angioedema in newborns. Pediatr Res. 1994;35: 184-7.
5. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6:24.
6. Farkas H, Fust G, Fekete B, Karadi I, Varga L. Eradication of Helicobacter pylori and improvement of hereditary angioneurotic oedema. Lancet. 2001;358:1695-6.
7. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100:153-61.
8. Drouet C, Désormeaux A, Robillard J, Ponard D, Bouillet L, Martin L, et al. Metallopeptidase activities in hereditary angioedema: Effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clinical Immunol. 2008;121: 429-33.
9. Farkas H, Varga L, Szeplaki G, Visby B, Harmat G, Bowen T. Management of hereditary angioedema in pediatric patients. Pediatrics. 2007;120:e713-e22.
10. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010; 363:513-22.
11. Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996;334:1630-4.
12. Krassilnikova S, Craig ET, Craig TJ. Summary of the international multicenter prospective angioedema C1-inhibitor trials 1 and 2 (IMPACT1 and 2). Expert Rev Clin Immunol. 2010;6:327-34.
13. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Int Med. 2001;161:714-8.
14. Longhurst HJ, Farkas H, Craig T, Aygören-Pürsün E, Bethune C, Bjorkander J, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6:22.
15. Choi G, Soeters MR, Farkas H, Varga L, Obtulowicz K, Bilo B, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion. 2007;47:1028-32.
16. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126:821-7.e14.
17. Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:523-9.
18. Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol. 2007;120:416-22.
19. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363: 523-31.